PMCB - PharmaCyte Biotech announces $10M share buyback program

PharmaCyte Biotech (NASDAQ:PMCB), a nano-cap biotech focused on cellular therapies said on Thursday that its board of directors authorized a share repurchase program to buy back up to $10M worth shares of the company’s outstanding common stock. The program takes effect immediately for a two-year period with PharmaCyte (PMCB) planning to fund the program with its available cash. The decision to implement a buyback program was taken up at a quarterly board meeting in March, PharmaCyte’s (PMCB) Chief Executive Kenneth L. Waggoner said. “It has been decided that since, unlike in year’s past, we are finally in a strong enough financial position we can allocate some of our capital in ways that will generate as much value as possible for our shareholders,” he added. The shares buybacks will be executed from time to time through open market transactions, negotiated block transactions or other means, the company said. The timing and

For further details see:

PharmaCyte Biotech announces $10M share buyback program